Marksans Pharma’s wholly owned subsidiary -- Relonchem has received Marketing Authorization for the product Sennosides 7.5 mg Tablets from UK Medicines & Healthcare Products Regulatory Agency.
Earlier, Relonchem had received marketing authorization for the product Gabapentin 50 mg/ml oral solution from UK Medicines & Healthcare Products Regulatory Agency.
Marksans Pharma is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets.